Lyka Labs Q1 FY27 Profit Surges 105% to ₹204.66 Lacs on Strong Revenue Growth
Lyka Labs reported a 105.44% increase in consolidated net profit to ₹204.66 Lacs for Q1 FY27. Consolidated net total income rose 26.95% to ₹4272.79 Lacs. Export revenue surged 68.03% to ₹1483.42 Lacs, while domestic revenue grew 15.91%. Standalone net profit jumped 159.04% to ₹210.01 Lacs.
The substantial increase in profits and revenue, especially the strong export growth, is a material development for the company's financial health and investor outlook.
The company reported significant year-on-year growth in both standalone and consolidated net profit and revenue, indicating strong financial performance.
Lyka Labs Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors approved these results in a meeting held on August 10, 2026.
Standalone Net Total Income increased by 42.67% to ₹4272.79 Lacs. Consolidated Net Total Income also saw a significant rise of 26.95% to ₹4272.79 Lacs. Domestic Revenue grew by 15.91% to ₹2652.11 Lacs, while Export Revenue surged by 68.03% to ₹1483.42 Lacs.
Standalone Net Profit rose by 159.04% to ₹210.01 Lacs, and Consolidated Net Profit increased by 105.44% to ₹204.66 Lacs. However, Standalone EBITDA margin decreased to 11.84% from 14.16% in the prior year's quarter, and Consolidated EBITDA margin declined to 11.74% from 13.07%.
Key revenue drivers included a 62.27% increase in Domestic Branded Formulation sales and a 97.83% rise in Branded Veterinary sales. Export Branded Formulation sales grew by 68.03%. The company operates in the manufacturing and marketing of finished formulations for human and animal healthcare.
What to do with a filing like this
Lyka Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lyka Labs Limited. Read the original for the full detail.